RxDoctor Payments Data

Lisa Kim, MD

Internal Medicine · Ellicott City, MDNPI 1982795753

Payments from drug & device makers

$1,429in general payments, 2019–2025

Across 46 payments — averaging $31.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amarin Pharma, Inc.$246
  • Novo Nordisk$237
  • Amgen$158
  • Lilly USA, LLC$154
  • AstraZeneca$148
  • Astellas Pharma US Inc$110
  • plus $376 from 8 others

What the payments were for

  • Food & beverage$1,33493%
  • Education$957%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,429 in reported general payments places this provider in the 75th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$166,208
Medicare patients
229
Services billed
1,854

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin243$163,076
JanuviaSitagliptin Phosphate124$97,565
TrulicityDulaglutide84$82,530
TradjentaLinagliptin111$63,796
FarxigaDapagliflozin Propanediol76$58,164
Lidocaine305$57,571
VascepaIcosapent Ethyl110$51,529
MounjaroTirzepatide42$43,051
MyrbetriqMirabegron70$36,150
EliquisApixaban19$15,901
Diclofenac Sodium149$14,036
Tresiba Flextouch U-200Insulin Degludec22$12,123
RestasisCyclosporine16$10,132
Icosapent Ethyl33$9,815
Fluticasone-SalmeterolFluticasone Propion/Salmeterol35$7,812

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$103$226,872354 claims
Lilly USA, LLCTrulicity, Mounjaro$154$125,581126 claims
MerckJanuvia, Janumet$13$104,549137 claims
AstraZenecaFarxiga$148$58,16476 claims
Astellas Pharma US IncMyrbetriq$110$36,15070 claims
GSKIncruse Ellipta$20$4,25112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Ellicott City

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →